Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) has earned a consensus recommendation of “Hold” from the nine analysts that are currently covering the firm, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, five have given a hold recommendation and three have assigned a buy recommendation to the company. The average 1 year price objective among brokers that have issued ratings on the stock in the last year is $25.00.
A number of analysts recently issued reports on LXRX shares. ValuEngine raised Lexicon Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Friday, January 25th. Zacks Investment Research raised Lexicon Pharmaceuticals from a “hold” rating to a “buy” rating and set a $6.50 price objective on the stock in a report on Thursday, January 24th. BidaskClub raised Lexicon Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Thursday. Finally, Wedbush increased their price objective on Lexicon Pharmaceuticals from $36.00 to $38.00 and gave the stock an “outperform” rating in a report on Monday, March 4th.
Several large investors have recently added to or reduced their stakes in LXRX. Pegasus Asset Management Inc. purchased a new stake in shares of Lexicon Pharmaceuticals in the 4th quarter valued at about $66,000. Paloma Partners Management Co purchased a new stake in shares of Lexicon Pharmaceuticals in the 4th quarter valued at about $73,000. D.A. Davidson & CO. purchased a new stake in shares of Lexicon Pharmaceuticals in the 4th quarter valued at about $87,000. CWM Advisors LLC raised its holdings in shares of Lexicon Pharmaceuticals by 30.2% in the 4th quarter. CWM Advisors LLC now owns 13,059 shares of the biopharmaceutical company’s stock valued at $87,000 after acquiring an additional 3,030 shares in the last quarter. Finally, Metropolitan Life Insurance Co. NY raised its holdings in shares of Lexicon Pharmaceuticals by 409.3% in the 4th quarter. Metropolitan Life Insurance Co. NY now owns 14,760 shares of the biopharmaceutical company’s stock valued at $98,000 after acquiring an additional 11,862 shares in the last quarter. 99.34% of the stock is currently owned by hedge funds and other institutional investors.
Lexicon Pharmaceuticals (NASDAQ:LXRX) last issued its quarterly earnings data on Wednesday, March 13th. The biopharmaceutical company reported ($0.16) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.28) by $0.12. The business had revenue of $17.10 million for the quarter, compared to analysts’ expectations of $13.33 million. Lexicon Pharmaceuticals had a negative return on equity of 1,247.65% and a negative net margin of 168.23%. The firm’s quarterly revenue was down 49.7% on a year-over-year basis. During the same quarter in the prior year, the firm posted ($0.27) EPS. As a group, research analysts predict that Lexicon Pharmaceuticals will post -1.28 earnings per share for the current year.
Lexicon Pharmaceuticals Company Profile
Lexicon Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of pharmaceutical products for the treatment of human diseases. The company offers XERMELO, an orally-delivered small molecule drug candidate for the treatment of carcinoid syndrome diarrhea in combination with somatostatin analog therapy in adults.
Featured Story: How a Strangle Strategy is different from a Straddle Strategy
Receive News & Ratings for Lexicon Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lexicon Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.